GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ryvu Therapeutics SA (WAR:RVU) » Definitions » Pretax Margin %

Ryvu Therapeutics (WAR:RVU) Pretax Margin % : -176.17% (As of Sep. 2024)


View and export this data going back to 2011. Start your Free Trial

What is Ryvu Therapeutics Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Ryvu Therapeutics's Pre-Tax Income for the three months ended in Sep. 2024 was zł-26.55 Mil. Ryvu Therapeutics's Revenue for the three months ended in Sep. 2024 was zł15.07 Mil. Therefore, Ryvu Therapeutics's pretax margin for the quarter that ended in Sep. 2024 was -176.17%.

The historical rank and industry rank for Ryvu Therapeutics's Pretax Margin % or its related term are showing as below:

WAR:RVU' s Pretax Margin % Range Over the Past 10 Years
Min: -1161.37   Med: -120.52   Max: 18.8
Current: -163.47


WAR:RVU's Pretax Margin % is ranked worse than
51.14% of 1013 companies
in the Biotechnology industry
Industry Median: -148.6 vs WAR:RVU: -163.47

Ryvu Therapeutics Pretax Margin % Historical Data

The historical data trend for Ryvu Therapeutics's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ryvu Therapeutics Pretax Margin % Chart

Ryvu Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,161.37 -198.62 -762.33 -203.35 -196.57

Ryvu Therapeutics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -151.55 -247.91 -89.68 -192.52 -176.17

Competitive Comparison of Ryvu Therapeutics's Pretax Margin %

For the Biotechnology subindustry, Ryvu Therapeutics's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ryvu Therapeutics's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ryvu Therapeutics's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Ryvu Therapeutics's Pretax Margin % falls into.



Ryvu Therapeutics Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Ryvu Therapeutics's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-92.112/46.86
=-196.57 %

Ryvu Therapeutics's Pretax Margin for the quarter that ended in Sep. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Sep. 2024 )/Revenue (Q: Sep. 2024 )
=-26.552/15.072
=-176.17 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ryvu Therapeutics  (WAR:RVU) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Ryvu Therapeutics Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Ryvu Therapeutics's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Ryvu Therapeutics Business Description

Traded in Other Exchanges
Address
Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.

Ryvu Therapeutics Headlines

No Headlines